PHVS Valuation

Pharvaris NV

Add to Watchlist

Advanced Chart

23.120

-0.23(-0.985%)1D

Overview
Forecast
Valuation
Earnings

PHVS Relative Valuation

PHVS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, PHVS is overvalued; if below, it's undervalued.

Historical Valuation

Pharvaris NV (PHVS) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -6.84. The fair price of Pharvaris NV (PHVS) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：23.79

Fair

-7.62

Trailing

Forward

-7.08

EV/EBITDA

Pharvaris NV. (PHVS) has a current EV/EBITDA of -7.08. The 5-year average EV/EBITDA is -4.37. The thresholds are as follows: Strongly Undervalued below -10.21, Undervalued between -10.21 and -7.29, Fairly Valued between -1.45 and -7.29, Overvalued between -1.45 and 1.47, and Strongly Overvalued above 1.47. The current Forward EV/EBITDA of -7.08 falls within the Historic Trend Line -Fairly Valued range.

-6.95

EV/EBIT

Pharvaris NV. (PHVS) has a current EV/EBIT of -6.95. The 5-year average EV/EBIT is -4.45. The thresholds are as follows: Strongly Undervalued below -10.56, Undervalued between -10.56 and -7.50, Fairly Valued between -1.39 and -7.50, Overvalued between -1.39 and 1.67, and Strongly Overvalued above 1.67. The current Forward EV/EBIT of -6.95 falls within the Historic Trend Line -Fairly Valued range.

0.00

Pharvaris NV. (PHVS) has a current PS of 0.00. The 5-year average PS is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward PS of 0.00 falls within the Strongly Undervalued range.

-10.43

P/OCF

Pharvaris NV. (PHVS) has a current P/OCF of -10.43. The 5-year average P/OCF is -7.02. The thresholds are as follows: Strongly Undervalued below -16.53, Undervalued between -16.53 and -11.78, Fairly Valued between -2.27 and -11.78, Overvalued between -2.27 and 2.48, and Strongly Overvalued above 2.48. The current Forward P/OCF of -10.43 falls within the Historic Trend Line -Fairly Valued range.

-8.74

P/FCF

Pharvaris NV. (PHVS) has a current P/FCF of -8.74. The 5-year average P/FCF is -5.88. The thresholds are as follows: Strongly Undervalued below -10.81, Undervalued between -10.81 and -8.35, Fairly Valued between -3.41 and -8.35, Overvalued between -3.41 and -0.95, and Strongly Overvalued above -0.95. The current Forward P/FCF of -8.74 falls within the Undervalued range.

Pharvaris NV (PHVS) has a current Price-to-Book (P/B) ratio of 5.86. Compared to its 3-year average P/B ratio of 3.03 , the current P/B ratio is approximately 93.75% higher. Relative to its 5-year average P/B ratio of 2.73, the current P/B ratio is about 114.97% higher. Pharvaris NV (PHVS) has a Forward Free Cash Flow (FCF) yield of approximately -9.51%. Compared to its 3-year average FCF yield of -16.62%, the current FCF yield is approximately -42.80% lower. Relative to its 5-year average FCF yield of -13.48% , the current FCF yield is about -29.50% lower.

5.95

P/B

Median3y

3.03

Median5y

2.73

-9.62

FCF Yield

Median3y

-16.62

Median5y

-13.48

Competitors Valuation Multiple

The average P/S ratio for PHVS's competitors is 4.06, providing a benchmark for relative valuation. Pharvaris NV Corp (PHVS) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

ARS Pharmaceuticals Inc

Amphastar Pharmaceuticals Inc

1.87

-4.38%

1.42B

Performance Decomposition

Market capitalization of PHVS increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of PHVS in the past 1 year is driven by Unknown.